VectivBio Holding, clinical-stage biopharmaceutical company specialising in novel transformational treatments for severe rare conditions announced the acquisition of Comet Therapeutics, a biotechnology company that has been developing drugs to address previously untreatable inherited metabolic diseases.
Tags :Joël Gyger
The team was led by Daniel Häusermann (Corporate/M&A - pictured) and included Luca Dal Molin (IP/IT), Stefan Gäumann (Real Estate), Aron Waltuch (Corporate/M&A)